Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients
Open accessThe DOI matches its Crossref record.
Abstract
Meeting abstracts Immunomodulation with pembrolizumab (anti-PD-1) has been shown to reach significant objective response (RR) and extend overall survival (OS) both in ipilimumab pre-treated and naive patients with metastatic melanoma. While this immunotherapy gives OS and OR benefits, it can also
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Studies claiming improved outcomes associated with irAEs can be found alongside studies reporting no apparent correlation, regardless of the type of ICI used (120, 127-130).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [130]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Bagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189
Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms
Fessas, P., Possamai, L. A., Clark, J., Daniels, E., Gudd, C., Mullish, B. H., Alexander, J. L., & Pinato, D. J. (2020) · Immunology · doi:10.1111/imm.13141 · Cited by 105
Lisberg, A. E., Tucker, D. A., Goldman, J. W., Wolf, B., Carroll, J., Hardy, A., Morris, K. K., Linares, P., Adame, C. R., Spiegel, M. L., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0063 · Cited by 105
“However, data on this subject are conflicting, as others have found no association between immune checkpoint–related AEs and response to checkpoint blockade in melanoma (16).”
BackgroundResultPathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity
Inno, A., Metro, G., Bironzo, P., Grimaldi, A. M., Grego, E., Nunno, V. D., Picasso, V., Massari, F., & Gori, S. (2017) · Tumori Journal · doi:10.5301/tj.5000625 · Cited by 71
“In fact, in a retrospective series of 47 patients with metastatic melanoma treated with pembrolizumab the authors did not identify a significant difference in terms of response rates or DCR between patients with and those without irAEs (161).”
BackgroundSelf-citationShafqat, H., Gourdin, T. S., & Sion, A. M. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.07.003 · Cited by 71
Metadata
- Authors
- Grimaldi, A., Simeone, E., Festino, L., Giannarelli, D., Palla, M., Caracò, C., Curvietto, M., Esposito, A., Grimaldi, M., Mozzillo, N., & Ascierto, P. A.
- Affiliations
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- Instituto Nazionale Tumori Regina Elena (IT)
- Università Cattolica del Sacro Cuore (IT)
- Corresponding author
- Ascierto, Paolo A
- ORCID
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2015
- Volume
- 3
- Issue
- Suppl 2
- Pages
- P186
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC4649387
- OpenAlex
- W2226252183
- Cited by
- 11
- References
- 0
- Citations by year
- 2024: 2 · 2021: 1 · 2020: 1 · 2019: 3 · 2018: 3 · 2017: 1
- Type
- conference abstract
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- pembrolizumab, immune-related adverse events, advanced melanoma, anti-PD-1 therapy, objective response rate, overall survival, immune checkpoint inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients. https://app.cochat.ai/papers/10.1186/2051-1426-3-s2-p186
- The paper
- Grimaldi, A., Simeone, E., Festino, L., Giannarelli, D., Palla, M., Caracò, C., Curvietto, M., Esposito, A., Grimaldi, M., Mozzillo, N., & Ascierto, P. A. (2015). Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1186/2051-1426-3-s2-p186
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.